Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Nadia Harbeck(Breast Center), Priya Rastogi(University of Pittsburgh), Miguel Martín(Hospital General Universitario Gregorio Marañón), Sara M. Tolaney(Dana-Farber Cancer Institute), Zhimin Shao(Fudan University Shanghai Cancer Center), Peter A. Fasching(Universitätsklinikum Erlangen), Chiun‐Sheng Huang(National Taiwan University Hospital), Georgina Garnica Jaliffe, A. Tryakin(Russian Cancer Research Center NN Blokhin), Matthew P. Goetz(Mayo Clinic in Florida), Hope S. Rugo(University of California, San Francisco), Elżbieta Senkus(Gdańsk Medical University), Laura Testa(D’Or Institute for Research and Education), Mariette Andersson(Rigshospitalet), Kenji Tamura(Tokyo National Hospital), Lucia Del Mastro(Ospedale Policlinico San Martino), Guenther G. Steger(Medical University of Vienna), Hans Kreipe(Medizinische Hochschule Hannover), Roberto Hegg, Joohyuk Sohn(Yonsei University), Valentina Guarneri(University of Padua), Javier Cortés(Vall d'Hebron Institute of Oncology), E.P. Hamilton(Sarah Cannon), Valérie André(Eli Lilly (United States)), Ran Wei(Eli Lilly (United States)), Susana Barriga(Eli Lilly (United States)), S. Sherwood(Eli Lilly (United States)), Tammy Forrester(Eli Lilly (United States)), Montserrat Muñoz-Mateu(Eli Lilly (United States)), Ashwin Shahir(Eli Lilly (United States)), Belén San Antonio(Eli Lilly (United States)), Sarah C. Nabinger(Eli Lilly (United States)), Masakazu Toi(Kyoto University Hospital), Stephen Johnston(Royal Marsden NHS Foundation Trust), Joyce O’Shaughnessy(Texas Oncology), M.M. Jimenez(Eli Lilly (United States)), Stephen Johnston(Royal Marsden NHS Foundation Trust), F. Boyle(Eli Lilly (United States)), Guenther G. Steger(Medical University of Vienna), Patrick Neven(Medizinische Hochschule Hannover), Zefei Jiang(Eli Lilly (United States)), Mario Campone(Kyoto University Hospital), Jens Huober(Texas Oncology), Chikako Shimizu(International Breast Cancer Study Group), I. Cicin(Kyoto University Hospital), Andrew Wardley, Sara M. Tolaney(Dana-Farber Cancer Institute), Gonzalo Gómez Abuin, J. J. Zarba(Texas Oncology), Elgene Lim(Texas Oncology), P. Sant(Medizinische Hochschule Hannover), Naishun Liao(Texas Oncology), Bo Christiansen(Eli Lilly (United States)), Natalja Eigėlienė(Texas Oncology), J. Martin-Babau(Texas Oncology), Johannes Ettl(Texas Oncology), D. Mavroudis(Royal Marsden NHS Foundation Trust), Joanne Chiu(Texas Oncology), Katalin Boér(Medizinische Hochschule Hannover), R. Nagarkar(Eli Lilly (United States)), Shani Paluch–Shimon(Texas Oncology), Luca Moscetti(Sarah Cannon), Yoshiatsu Sagara(Texas Oncology), S.-B. Kim(Eli Lilly (United States)), Rui M. B. Maciel(Eli Lilly (United States)), Vivianne C. G. Tjan‐Heijnen(Eli Lilly (United States)), Reuben Broom(Eli Lilly (United States)), Aleksandra Łacko, M. Schenker(Kyoto University Hospital), Nikita Volkov(Texas Oncology), Yoon Sim Yap(Texas Oncology), M.A. Coccia-Portugal(Kyoto University Hospital), J. Ángel García Sáenz(Texas Oncology), Anne Andersson(Rigshospitalet), Tai-Jong Chao, Erhan Gökmen(Texas Oncology), Hakan Harputluoğlu(Texas Oncology), O. Berzoy(Texas Oncology), Debra A. Patt(Royal Marsden NHS Foundation Trust), Heather L. McArthur(Texas Oncology), Helen K. Chew(Texas Oncology), Pavani Chalasani(Medizinische Hochschule Hannover), Peter A. Kaufman(Medizinische Hochschule Hannover), Karen L. Tedesco(Medizinische Hochschule Hannover), Stephanie L. Graff
Cited by 374Open Access